1. Home
  2. ACRV vs ONL Comparison

ACRV vs ONL Comparison

Compare ACRV & ONL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • ONL
  • Stock Information
  • Founded
  • ACRV 2018
  • ONL 2021
  • Country
  • ACRV United States
  • ONL United States
  • Employees
  • ACRV N/A
  • ONL N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • ONL Real Estate Investment Trusts
  • Sector
  • ACRV Health Care
  • ONL Real Estate
  • Exchange
  • ACRV Nasdaq
  • ONL Nasdaq
  • Market Cap
  • ACRV 189.0M
  • ONL 223.5M
  • IPO Year
  • ACRV 2022
  • ONL N/A
  • Fundamental
  • Price
  • ACRV $5.54
  • ONL $4.03
  • Analyst Decision
  • ACRV Strong Buy
  • ONL Hold
  • Analyst Count
  • ACRV 6
  • ONL 1
  • Target Price
  • ACRV $22.40
  • ONL N/A
  • AVG Volume (30 Days)
  • ACRV 69.3K
  • ONL 227.4K
  • Earning Date
  • ACRV 03-27-2025
  • ONL 03-05-2025
  • Dividend Yield
  • ACRV N/A
  • ONL 9.93%
  • EPS Growth
  • ACRV N/A
  • ONL N/A
  • EPS
  • ACRV N/A
  • ONL N/A
  • Revenue
  • ACRV N/A
  • ONL $169,644,000.00
  • Revenue This Year
  • ACRV N/A
  • ONL N/A
  • Revenue Next Year
  • ACRV N/A
  • ONL N/A
  • P/E Ratio
  • ACRV N/A
  • ONL N/A
  • Revenue Growth
  • ACRV N/A
  • ONL N/A
  • 52 Week Low
  • ACRV $3.83
  • ONL $3.01
  • 52 Week High
  • ACRV $11.90
  • ONL $4.51
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 47.59
  • ONL 51.12
  • Support Level
  • ACRV $5.00
  • ONL $3.96
  • Resistance Level
  • ACRV $6.08
  • ONL $4.15
  • Average True Range (ATR)
  • ACRV 0.64
  • ONL 0.10
  • MACD
  • ACRV 0.01
  • ONL -0.00
  • Stochastic Oscillator
  • ACRV 25.68
  • ONL 36.84

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About ONL Orion Office REIT Inc.

Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.

Share on Social Networks: